Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs

Paris-based Bioptimus has announced a plan to build the world's largest spatially-anchored map of human tissue at clinical scale: 100,000 patient specimens, spanning the United States, Europe, and Asia. The initiative, called STELA — Spatial Tissue Embedding Learning Atlas — is designed to be the data engine behind M-Optimus, the company's multimodal “world model” for biology. It is an audacious data infrastructure bet. It is also, so far, light on the details that matter most.

The announcement, made alongside spatial genomics company 10x Genomics and Broad Clinical Labs, describes a dataset that would dwarf existing spatial biology resources by a claimed factor of 20. Using 10x Genomics' Xenium spatial transcriptomics platform as its foundation, STELA would integrate histopathology imaging, multi-omics profiles, and longitudinal clinical records into a single harmonized atlas. Broad Clinical Labs brings high-throughput processing muscle. According to Bioptimus's press release on PR Newswire, the goal is to make tissue-level molecular data “actionable” for clinicians at participating institutions — not just for the patient it came from, but for future patients too.

Bioptimus, founded by former Google Brain and Owkin scientists, has raised $76 million to date — $35 million in seed funding and a $41 million Series A led by Cathay Innovation with participation from Sofinnova Partners, Bpifrance, Andera Partners, Hitachi Ventures, and others, per the company's funding announcement. That balance sheet gives them runway to actually build what they're describing. Their first pathology model, H-Optimus-0, has logged benchmark results against models from Harvard Medical School and the University of Leeds. M-Optimus, announced in December 2025, already integrates histology, bulk RNA sequencing, spatial transcriptomics, and clinical data into a unified model.

But the hard part isn't building the model. It's getting the data in the first place.

The consent and governance problem across 100,000 patients across three continents is not a footnote — it is the core challenge. Operating simultaneously under the U.S. Health Insurance Portability and Accountability Act (HIPAA), the European General Data Protection Regulation (GDPR), and Asian privacy frameworks requires more than legal agreements; it requires a consent architecture that answers: which patients consented to multi-omics tissue profiling for AI training, not just clinical use? How is de-identification verified at scale? Who retains control over data that leaves a hospital system? The press release says participating institutions will follow “standardized protocols.” It does not say what those protocols are, who certifies them, or how conflicts between jurisdictions are resolved. This is not a gap a company can paper over with a slide deck. The Bioptimus PR notes that participating hospitals will receive “rich spatial characterization” in return for samples — a reasonable exchange — but leaves open the question of what happens to that characterization downstream when a pharma partner comes calling.

Spatial biology data at clinical scale is genuinely hard to harmonize, which is why it hasn't been done at this size before. A 2025 analysis from Elucidata on spatial biology challenges notes that patient-derived samples create compounding privacy obligations, that institutional data structures vary enormously even within a single country, and that there is no standardized format for spatial transcriptomics datasets — a gap that Nature Biotechnology separately flagged in December 2025 with a multi-institute effort to establish standard metrics. STELA is attempting to do at 100,000 specimens what existing atlases have done at single-digit thousands.

On the competitive side, Bioptimus is positioning itself as data infrastructure for the AI-biology stack. Recursion Pharmaceuticals, BioNTex, and Google's DeepMind have all moved in this direction — DeepMind with AlphaFold, which solved protein structure; Recursion with its own map of biological perturbations at scale. What makes the 10x Genomics partnership potentially different is commercial reach: Xenium is already deployed in academic medical centers and pharma labs worldwide, giving Bioptimus an installed base of compatible instruments rather than requiring new hardware partnerships from scratch. Whether hospital systems will actually share patient tissue data at the scale Bioptimus is projecting is the central open question — one that the consent architecture will answer one way or the other.

Jean-Philippe Vert, Bioptimus co-founder and CEO, framed the vision in the announcement: “We envision a world where every patient can contribute insights to better inform the care and treatment outcomes of future patients.” That is a genuinely compelling north star. The question is whether the world they're describing has the governance scaffolding to support it — and right now, that scaffolding isn't in the press release.

STELA is a meaningful bet on data as the bottleneck for biological AI. Whether it succeeds depends less on the quality of the Xenium platform or the M-Optimus model than on whether Bioptimus can build the consent infrastructure fast enough to actually collect 100,000 specimens across three continents without breaking the trust of the patients those specimens came from.